98%
921
2 minutes
20
Background: Medication adherence in asthmatic patients enhances the effectiveness of treatments, but some studies in low and middle-income countries still show some limitations. Our study aimed to determine if pharmacist-led interventions could increase medication adherence, improve treatment effectiveness, and relieve symptom severity in outpatients with asthma.
Methods: We conducted a randomized, controlled trial on 247 asthmatic outpatients (aged ≥ 16) with a 1:1 ratio randomization at the hospitalization time and repeated after 1-month discharge. The primary outcome was to detect the difference in medication adherence between groups. Adherence was assessed by the general medication adherence scale (GMAS). Data collected by questionnaire was coded and entered into SPSS_20 for statistical analysis; Results: 247 patients (123 intervention, 124 control) were enrolled (61.1% male). After intervention, the adherence rate was higher among the intervention group than the control group (94.3% vs. 82.8%, = 0.001). Patient behavior and knowledge were enhanced in the intervention group ( < 0.05). Asthma symptoms were relieved in the intervention group ( = 0.014). Pharmacist-led interventions on adherence rate were higher with OR: 3.550, 95% CI: 1.378-9.143, = 0.009.
Conclusions: pharmaceutical intervention could improve medication adherence, treatment efficacy, and the outcome should not be taken for granted; further research should be carried out in this regard.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295109 | PMC |
http://dx.doi.org/10.3390/arm91030020 | DOI Listing |
J Crohns Colitis
September 2025
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Background & Aims: Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes.
View Article and Find Full Text PDFClin Ther
September 2025
Avadel Pharmaceuticals, Chesterfield, Missouri.
Purpose: Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of age or older with narcolepsy. ON-SXB contains both immediate-release and pH-dependent, controlled-release granules designed to be reconstituted in water and administered orally once at bedtime.
View Article and Find Full Text PDFVaccine
September 2025
Department of Psychology, University of Miami, Coral Gables, FL, USA. Electronic address:
Existing inequities are exacerbated during the COVID-19 pandemic. Similar to HIV, COVID-19 disproportionately affects Black and other communities of color. Among Black women living with HIV (BWLWH) this study examined the relationship between community level and individual level social determinants of health and time to COVID-19 vaccine uptake.
View Article and Find Full Text PDFJ Pharm Pract
September 2025
Department of Pharmacy, Guthrie Robert Packer Hospital, Sayre, PA, USA.
Telehealth in the ICU (Tele-ICU) may improve patient outcomes and optimize utilization of high acuity intensive care unit (ICU) beds. However, the relationship between tele-ICU and medication regimen complexity-ICU (MRC-ICU) score is unexplored. To assess the effect of tele-ICU on MRC-ICU score and describe pharmacists' work.
View Article and Find Full Text PDFObes Surg
September 2025
Department of Minimally Invasive Digestive Surgery, Antoine Béclère Hospital, AP-HP, 157 Rue de La Porte de Trivaux, 92141 Clamart, Clamart, France.
Background: Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS.
View Article and Find Full Text PDF